Dysregulation of cellular signaling by HER2/neu in breast cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in Oncology

• Publication date

  2003-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2003.08.006PMID 14613025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53*

  2002cited by this paper
• ErbB-β-Catenin Complexes Are Associated with Human Infiltrating Ductal Breast and Murine Mammary Tumor Virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic Carcinomas*

  2002cited by this paper
• PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit.

  2002cited by this paper
• Signal transduction: Molecular ticket to enter cells

  2002cited by this paper
• Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

  2002cited by this paper
• WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase.

  2002cited by this paper
• Phosphorylation of HDM2 by Akt

  2002cited by this paper
• Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.

  2002cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether

  2002cited by this paper
• Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis

  2002cited by this paper
• The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression.

  2002cited by this paper
• PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy*

  2002cited by this paper
• PTEN Blocks Tumor Necrosis Factor-induced NF-κB-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit*

  2002cited by this paper
• Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

  2002cited by this paper
• Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

  2002cited by this paper
• IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development

  2001cited by this paper
• Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

  2001cited by this paper
• Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38*

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Regulation of PTEN transcription by p53.

  2001cited by this paper
• IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.

  2001cited by this paper
• Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

  2001cited by this paper
• HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

  2001cited by this paper
• Biology of HER2 and Its Importance in Breast Cancer

  2001cited by this paper
• Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

  2001cited by this paper
• Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.

  2001cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

  2001cited by this paper
• Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN

  2001cited by this paper
• Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex*

  2001cited by this paper
• HER2 overexpression and cancer targeting.

  2001cited by this paper
• Series Introduction: The transcription factor NF-κB and human disease

  2001cited by this paper
• Series introduction: the transcription factor NF-kappaB and human disease.

  2001cited by this paper
• Targeting HER2: recent developments and future directions for breast cancer patients.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

  2001cited by this paper
• Regulation of p53 function.

  2001cited by this paper
• Correlation of p27 protein expression with HER‐2/neu expression in breast cancer

  2001cited by this paper
• A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

  2001cited by this paper
• PTEN: life as a tumor suppressor.

  2001cited by this paper
• The INK4a/ARF network in tumour suppression

  2001cited by this paper
• MDM2--master regulator of the p53 tumor suppressor protein.

  2000cited by this paper
• Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

  2000cited by this paper
• Cbl-b regulates the CD28 dependence of T-cell activation

  2000cited by this paper
• Role of erbB2 in breast cancer chemosensitivity.

  2000cited by this paper
• Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

  2000cited by this paper
• The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

  2000cited by this paper
• C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines

  2000cited by this paper
• Checkpoints: How to activate p53

  2000cited by this paper
• HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.

  2000cited by this paper
• Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27*

  2000cited by this paper
• Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.

  2000cited by this paper
• Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion.

  2000cited by this paper
• Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3

  2000cited by this paper
• Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

  2000cited by this paper
• Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.

  2000cited by this paper
• The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance.

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Akt Suppresses Apoptosis by Stimulating the Transactivation Potential of the RelA/p65 Subunit of NF-κB

  2000cited by this paper
• Strategies for manipulating the p53 pathway in the treatment of human cancer.

  2000cited by this paper
• Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.

  2000cited by this paper
• The ARF/p53 pathway.

  2000cited by this paper
• Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines.

  2000cited by this paper
• c-Cbl Is a Suppressor of the Neu Oncogene*

  2000cited by this paper
• Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells

  2000cited by this paper
• β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression

  2000cited by this paper
• HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway*

  2000cited by this paper
• Casein Kinase II Phosphorylation of E-cadherin Increases E-cadherin/β-Catenin Interaction and Strengthens Cell-Cell Adhesion*

  2000cited by this paper
• Strategies for manipulating the p53 pathway in the treatment of human cancer

  2000cited by this paper
• p53: death star.

  2000cited by this paper
• Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation

  1999cited by this paper
• Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.

  1999cited by this paper
• β-Catenin regulates expression of cyclin D1 in colon carcinoma cells

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis*

  1999cited by this paper
• Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

  1999cited by this paper
• I κ B α Gene Transfer Is Cytotoxic to Squamous-Cell Lung Cancer Cells and Sensitizes Them to Tumor Necrosis Factor- α –Mediated Cell Death

  1999cited by this paper
• Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

  1999cited by this paper
• E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IκB Kinases and Nuclear Factor κB Activities*

  1999cited by this paper
• Nucleolar Arf sequesters Mdm2 and activates p53

  1999cited by this paper
• The oncogenic activation of beta-catenin.

  1999cited by this paper
• IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death.

  1999cited by this paper
• E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities.

  1999cited by this paper
• Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

  1999cited by this paper
• Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

  1999cited by this paper
• The oncogenic activation of β-catenin

  1999cited by this paper
• Protein translocation in apoptosis.

  1999cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• Identification of c-MYC as a target of the APC pathway.

  1998cited by this paper
• Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.

  1998cited by this paper
• p300/MDM2 complexes participate in MDM2-mediated p53 degradation.

  1998cited by this paper
• A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

  1998cited by this paper
• Tissue Hyperplasia and Enhanced T-Cell Signalling via ZAP-70 in c-Cbl-Deficient Mice

  1998cited by this paper
• A Phase I Multicenter Study of E1A Gene Therapy for Patients with Metastatic Breast Cancer and Epithelial Ovarian Cancer That Overexpresses HER-2/neu or Epithelial Ovarian Cancer. M.D. Anderson Cancer Center, Houston, Texas

  1998cited by this paper
• TGF-beta signal transduction.

  1998cited by this paper
• Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties

  1998cited by this paper

• A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer

  2026cites this paper
• Aurora B inhibition induces polyploidy and mitotic catastrophe in HER2-amplified breast cancer: Telomere shortening as a potential anticancer mechanism of AZD1152-HQPA.

  2025cites this paper
• [18F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients

  2025cites this paper
• Targeting cytokine and chemokine signaling pathways for cancer therapy

  2024cites this paper
• The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

  2024cites this paper
• HER2 puzzle pieces: Non-Coding RNAs as keys to mechanisms, chemoresistance, and clinical outcomes in Ovarian cancer.

  2024cites this paper
• Men's mutagenomic applications and advances in malignancies treatment: a narrative review

  2024cites this paper
• A review on endoplasmic reticulum-dependent anti-breast cancer activity of herbal drugs: possible challenges and opportunities

  2024cites this paper
• A Model Combining Conventional Ultrasound Characteristics, Strain Elastography and Clinicopathological Features to Predict Ki-67 Expression in Small Breast Cancer

  2024cites this paper
• Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions

  2023cites this paper
• Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells

  2023cites this paper
• Combining conventional ultrasound and ultrasound elastography to predict HER2 status in patients with breast cancer

  2023cites this paper
• Immunohistochemical Subtypes of The Breast Cancer in The Ultrasound and Clinical Aspect – Literature Review

  2022cites this paper
• Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer

  2021cites this paper
• Computational Studies in Breast Cancer

  2021cites this paper
• Cancer du sein HER2-low : comment un concept biologique s’immisce-t-il dans la décision thérapeutique ?

  2021cites this paper
• A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report

  2021cites this paper
• Imaging features of breast cancer molecular subtypes: state of the art

  2020cites this paper
• Computational studies on breast cancer analysis

  2020cites this paper
• Antibody-Directed Metal-Organic Framework Nanoparticles for Targeted Drug Delivery.

  2019cites this paper
• Peptide-Based Vaccines: Current Progress and Future Challenges

  2019cites this paper
• Correlation of digital mammography and digital breast tomosynthesis features of self-detected breast cancers with human epidermal growth factor receptor type 2/neu status

  2019cites this paper
• Evolving paradigms on the interplay of mitochondrial Hsp70 chaperone system in cell survival and senescence

  2019cites this paper
• Analysis of HER-2/neu Receptor Expression and the Level of Neuronal Apoptosis in HER-2/neu Transgenic Mice during Aging

  2019cites this paper
• CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers

  2018cites this paper
• D Rhamnose β-Hederin against human breast cancer by reducing tumor-derived exosomes

  2018cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• Head and Neck Tumors

  2015cites this paper
• Black Rice Anthocyanins Suppress Metastasis of Breast Cancer Cells by Targeting RAS/RAF/MAPK Pathway

  2015cites this paper
• Efecto de la inhibición de la clusterina sobre la sensibilidad a los inhibidores de proteínas quinasas en células tumorales de mama

  2015cites this paper
• High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus

  2014cites this paper
• Imaging Features of HER 2 Overexpression in Breast Cancer : A Systematic Review and Meta-analysis

  2014cites this paper
• Computational Methods for Breast Cancer Diagnosis, Prognosis, and Treatment Prediction

  2014cites this paper
• Immunogenicity and Therapeutic Efficacy of a Dual-Component Genetic Cancer Vaccine Cotargeting Carcinoembryonic Antigen and HER2/neu in Preclinical Models

  2014cites this paper
• Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

  2014cites this paper
• APOPTOTIC PATHWAYS IN HUMAN BREAST CANCER CELL MODELS (MCF-7 AND MDA-MB-231) INDUCED BY RICE BRAN DERIVED PENTAPEPTIDE

  2014cites this paper
• Introduction of HER-2 and a Short Review on Its Role in Prognosis and Treatment of Breast Cancer

  2014cites this paper
• Discordance Between HER-2 / NEU Expression Assessed Using Immunohistochemistry ( IHC ) and Fluorescence in Situ Hybridization ( FISH ) : Is It Important to Detect ?

  2013cites this paper
• The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study

  2013cites this paper
• Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis

  2013cites this paper
• Prise en charge thérapeutique des cancers du sein infiltrants localisés

  2013cites this paper
• Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?

  2013cites this paper
• New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

  2012cites this paper
• Mechanistic Investigation of Tolfenamic Acid, Betulinic Acid, and Aspirin in Anti-Cancer Therapy

  2012cites this paper
• MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC)

  2012cites this paper
• Monoclonal Antibody-Based Targeted Therapy in Breast Cancer

  2012cites this paper
• Fonctions de l'oncoprotéine LMO2 déterminées par ses interactions protéiques

  2012cites this paper
• Clinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival model

  2012cites this paper
• Translating Mammary Stem Cell and Cancer Stem Cell Biology to the Clinics

  2012cites this paper
• α‐Tocopheryloxyacetic acid is superior to α‐tocopheryl succinate in suppressing HER2‐high breast carcinomas due to its higher stability

  2012cites this paper
• Down-regulation of vascular endothelial growth factor expression by anti-her2/neu single chain antibodies

  2012cites this paper
• Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer

  2012cites this paper
• Tracking mammary epithelial cell lineage and cell divisions in the normal mammary gland and mammary neoplasia using transgenic mice

  2011cites this paper
• Anticorpos monoclonais contra receptor HER2:produção, caracterização e avaliação para uso em testes diagnósticos de tumores de mama humano e canino

  2011cites this paper
• Apc Mutation Enhances PyMT-Induced Mammary Tumorigenesis

  2011cites this paper
• Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance

  2010cites this paper
• Cancer esearch cular and Cellular Pathobiology ical Roles of DMP 1 in Human Epidermal Growth Factor eptor 2 / neu-Arf-p 53 Signaling and Breast R cer Development

  2010cites this paper
• Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition*

  2010cites this paper
• Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

  2010cites this paper
• Key signaling nodes in mammary gland development and cancer: β-catenin

  2010cites this paper
• New Molecular Therapeutic Interventions: The Case of Breast Cancers

  2010cites this paper
• The Relationship Between Insulin Resistance and Hyperinsulinemia on Mammary Cancer Growth and Development

  2010cites this paper
• A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer

  2009cites this paper
• Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection

  2009cites this paper
• Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

  2009cites this paper
• The Role of EGFR, HER 2-4, Heregulin and Downstream Signalling in Prostate Adenocarcinoma

  2008cites this paper
• REG1A Expression is an Independent Factor Predictive of Poor Prognosis in Patients with Breast Cancer

  2008cites this paper
• Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines.

  2008cites this paper
• Autocrine NGFβ/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines

  2008cites this paper
• RHEB expression in fibroadenomas of the breast

  2008cites this paper
• Molecular Mechanisms Underlying the Oncogenic Function of SS18 and SSX

  2008cites this paper
• Unraveling the biologic and clinical complexities of HER2.

  2008cites this paper
• Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

  2008cites this paper
• Negative regulation of signaling by the EGFR family

  2008cites this paper
• Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

  2008cites this paper
• Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria.

  2007cites this paper
• Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors

  2007cites this paper
• HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

  2007cites this paper
• HER2 testing: a review of detection methodologies and their clinical performance

  2007cites this paper
• A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression.

  2007cites this paper
• Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.

  2007cites this paper
• Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression

  2007cites this paper
• Prognostic markers in triple‐negative breast cancer

  2007influential citation
• Vitamin E analogues and immune response in cancer treatment.

  2007cites this paper
• COX-2 Expression in Hepatocellular Carcinoma is an Initiation Event; While EGF Receptor Expression with Downstream Pathway Activation is a Prognostic Predictor of Survival

  2007cites this paper
• Overexpression of ErbB2 in the exocrine pancreas induces an inflammatory response but not increased proliferation

  2007cites this paper
• The Emerging Role of Pharmacogenomics in Biologics

  2007cites this paper
• A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease

  2006cites this paper
• ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.

  2006cites this paper
• Adiponectin: a link between obesity and cancer

  2006cites this paper
• Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation.

  2006cites this paper
• Twenty years of systemic therapy for breast cancer.

  2006cites this paper
• Vitamin E analogs as anticancer agents

  2006cites this paper
• Vitamin E analogues as anti-cancer agents: The role of modulation of apoptosis signalling pathways

  2006cites this paper
• Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells.

  2006cites this paper
• Overexpressing Breast Cancer Cells − 3-Gallate in Her-2 / neu Resistance to the Green Tea Polyphenol Epigallocatechin Mitogen-Activated Protein Kinase Signaling as a Mediator of Microarray-Assisted Pathway Analysis Identifies

  2006cites this paper
• Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression.

  2006cites this paper
• Her-2 targeted therapy: Beyond breast cancer and trastuzumab

  2006cites this paper
• SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.

  2006cites this paper
• Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines.

  2006cites this paper